GEHC

Business Context and Reporting Period

Company: GE Healthcare Technologies Inc. (GEHC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A leading global provider of advanced medical technology, pharmaceutical diagnostics, and AI/cloud software solutions. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It serves customers in over 160 countries with approximately 54,000 employees.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Revenue Growth: Driven by strong performance in PDx (+15.6%), Imaging (+4.4%), and AVS (+4.3%). PCS declined -1.2% due to lower Life Support Solutions revenue. China region revenues decreased 4.6% due to local competition and procurement policies.
• Margin Pressure: Gross profit margin decreased 170 basis points to 40.0% (implied from data) due to cost inflation and incremental tariffs. Operating income margin increased slightly to 13.4%.
• Tariff Impact: New U.S. tariffs imposed in 2025 materially impacted operating income by approximately $245 million and cash flows by $285 million, primarily due to bilateral U.S.-China tariffs and tariffs on global imports.
• Acquisitions: Completed the acquisition of the remaining 50% interest in Nihon Medi-Physics (NMP) for $271 million net cash, recognizing a $97 million gain on remeasurement. Also acquired icometrix NV for ~$98 million.
• Debt Structure: Issued $2.75 billion in new senior unsecured notes to fund operations and the proposed Intelerad acquisition, partially offset by repaying $1.5 billion in maturing notes.

Guidance, Outlook, and Risks

• Outlook: Management expects continued material impact from tariffs if they remain at current levels. The company is taking mitigation actions but does not expect to fully offset additional costs.
• Strategic Transactions: Announced an agreement to acquire Intelerad for $2.3 billion, expected to close in H1 2026. A $750 million delayed draw term loan was secured to fund this.
• Key Risks:
  • Geopolitics & Trade: Ongoing U.S.-China trade tensions, tariffs, and the Russia-Ukraine conflict affecting supply chains and market access.
  • Regulatory: Stringent global regulations on medical devices, data privacy (GDPR, HIPAA), and anti-corruption laws (FCPA).
  • Supply Chain: Reliance on single-source suppliers for critical raw materials (helium, rare earth minerals) and potential disruptions.
  • Cybersecurity: Risks associated with connected medical devices and AI/cloud solutions.
• Unusual Items: A $97 million non-operating gain from the NMP equity method investment remeasurement. Spin-Off and separation costs decreased significantly to $38 million from $251 million in the prior year.

Investor Verification Checklist

• Tariff Mitigation: Verify the specific actions taken to offset the $245 million operating income impact from tariffs and the sustainability of these measures.
• China Market Dynamics: Assess the long-term impact of Volume Based Procurement (VBP) policies and local competition on the Imaging and AVS segments in China.
• Intelerad Acquisition: Review the integration plan and regulatory approval status for the $2.3 billion Intelerad deal, including the mandatory redemption clause on new debt if the deal fails.
• Debt Covenants: Confirm compliance with the maximum consolidated net leverage ratio covenant under the new credit facilities.
• Pension Obligations: Monitor the funded status of U.S. pension plans (90% funded) and the impact of discount rate changes on future benefit costs.
• Legal Proceedings: Track the status of the Anti-Terrorism Act litigation regarding contracts with the Iraqi Ministry of Health, recently remanded by the D.C. Circuit.